Table 2.
Results of the sEMG measurements at the baseline and after the last therapy for both treated groups (G1 and G2) and control subjects (G3) presented as mean followed by 95% confidence interval in brackets
| Group | Peak MVC (μV) |
Average MVC (μV) |
Resting level (μV) |
Endurance (s) |
||||
|---|---|---|---|---|---|---|---|---|
| Baseline | After | Baseline | After | Baseline | After | Baseline | After | |
| G1 (n = 50) | 19.49† (2.31) | 30.06†,∗∗∗ (3.75) | 11.33† (1.54) | 17.99†,∗ (2.50) | 3.83†,∗ (0.82) | 2.08 (0.38) | 27.86†,∗∗ (4.17) | 41.30†,∗∗∗ (5.21) |
| G2 (n = 25) | 19.56† (2.93) | 21.00† (2.82) | 13.39† (2.46) | 14.30† (2.42) | 2.42 (0.45) | 3.94†,∗∗∗ (0.60) | 18.20† (2.85) | 24.80† (3.12) |
| G3 (n = 20) | 41.96 (2.51) | - | 32.69 (1.88) | - | 1.90 (0.63) | - | 62.25 (3.68) | - |
EMG = electromyography; MVC = maximal voluntary contraction; sEMG = surface electromyography.
Significantly different results (P ≤ .002) against control are depicted by† and ∗ denotes significantly higher EMG values for comparison of G1 and G2.
∗P < .05, ∗∗P < .01, ∗∗∗P < .001.